Skip to content

Validation of Sleep Apnea Screening Device

Wireless Sensor Patch for Reducing Barriers to In-home Sleep Apnea Screening

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02814227
Enrollment
52
Registered
2016-06-27
Start date
2014-09-30
Completion date
2015-12-31
Last updated
2023-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea

Keywords

obstructive sleep apnea screening device

Brief summary

Obstructive sleep apnea (OSA) is the most common type of sleep apnea. OSA affects an estimated 18-40 million adults and 0.7-3% of all children in the US. The marketplace currently does not have an affordable, easy-to-use, over-the-counter, home-based OSA screening device. An affordable, available, FDA-approved and easy-to-use over-the-counter OSA screening tool would allow greater screening of at-risk individuals, especially in underserved communities with low socioeconomic status, hopefully encouraging a greater proportion of such individuals to seek treatment for their condition. The specific goal of this project is to compare the Zansors® micro sleep sensor screening device against gold-standard polysomnography to establish the device's preliminary validity to screen for OSA accurately.

Detailed description

Obstructive Sleep Apnea (OSA) results in tiredness, depression and fatigue, and has several associated common comorbidities. It is believed that over 80% of OSA remains undiagnosed. Poorer and disadvantaged communities are at higher risk for sleep disorders, including OSA, even after accounting for other risk factors. The gold-standard method for diagnosing OSA is in-laboratory polysomnography; however, this procedure is generally available only to patients with health insurance due to its high cost. As a result, communities at particularly high risk for OSA are less likely to have this serious sleep disorder appropriately diagnosed and treated. An affordable, available, FDA-approved and easy-to-use over-the-counter OSA screening tool would allow greater screening of at-risk individuals, especially in underserved communities with low socioeconomic status, hopefully encouraging a greater proportion of such individuals to seek treatment for their condition. Zansors® has developed a bioengineered, semiconductor prototype that measures breathing and movement during sleep. It is a 1.5 x 2.5 x 0.2 inch wireless package using four key technologies: 1. an adjustable microphone; 2. a 3-axis accelerometer; 3. embedded algorithms to measure sleep events; and 4. acrylic adhesive. The product will be designed as an FDA-approved over-the-counter device that the patient can wear during sleep and wake up with a color score of red, yellow, or green depending on their sleep apnea status. The features of this product include that it is home-based; easy to use; non-invasive; wireless; disposable; low cost ($20-50); and presents easily understandable test results. However, such a device must first be validated against gold-standard polysomnography. The specific goal of this project is to compare the Zansors® micro sleep sensor screening device against gold-standard polysomnography to establish the device's preliminary validity to screen for OSA accurately.

Interventions

DEVICEZansors® sleep screening device

Intervention is the validation of a sleep apnea screening device against the gold-standard assessment of in-laboratory polysomnography

Sponsors

Zansors
CollaboratorINDUSTRY
University of Michigan
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Must be over 18 and referred by medical staff for an overnight assessment for suspected sleep apnea

Exclusion criteria

* Pregnancy * Heart disease including congestive heart failure or a pacemaker * Breathing disorder (emphysema or chronic obstructive breathing disorder) * Neurological disorder such as Parkinson's Disease * Restless leg syndrome or Periodic limb movement * Allergies to metal * Pre-existing skin conditions where sensor would be attached

Design outcomes

Primary

MeasureTime frameDescription
Specificity8 hoursSpecificity of Zansors' device to detect apnea events compared to gold-standard polysomnography over an 8-hour period of sleep at 30-second intervals

Secondary

MeasureTime frameDescription
Sensitivity8 hoursSensitivity of Zansors' device to detect apnea events compared to gold-standard polysomnography over an 8-hour period of sleep at 30-second intervals
Positive Predictive Value (PPV)8 hoursPPV of Zansors' device to detect apnea events compared to gold-standard polysomnography over an 8-hour period of sleep at 30-second intervals
Negative Predictive Value (NPV)8 hoursNPV of Zansors' device to detect apnea events compared to gold-standard polysomnography over an 8-hour period of sleep at 30-second intervals

Countries

United States

Participant flow

Participants by arm

ArmCount
Zansors® Sleep Screening Device
Zansors device compared to overnight polysomnography Zansors® sleep screening device: Intervention is the validation of a sleep apnea screening device against the gold-standard assessment of in-laboratory polysomnography
52
Total52

Baseline characteristics

CharacteristicZansors® Sleep Screening Device
Age, Continuous47.8 years
STANDARD_DEVIATION 13.3
Region of Enrollment
United States
52 participants
Sex: Female, Male
Female
29 Participants
Sex: Female, Male
Male
23 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 52
serious
Total, serious adverse events
0 / 52

Outcome results

Primary

Specificity

Specificity of Zansors' device to detect apnea events compared to gold-standard polysomnography over an 8-hour period of sleep at 30-second intervals

Time frame: 8 hours

ArmMeasureValue (NUMBER)
Zansors® Sleep Screening DeviceSpecificity71.4 percentage of true negatives
Secondary

Negative Predictive Value (NPV)

NPV of Zansors' device to detect apnea events compared to gold-standard polysomnography over an 8-hour period of sleep at 30-second intervals

Time frame: 8 hours

ArmMeasureValue (NUMBER)
Zansors® Sleep Screening DeviceNegative Predictive Value (NPV)0.77 negative predictive value
Secondary

Positive Predictive Value (PPV)

PPV of Zansors' device to detect apnea events compared to gold-standard polysomnography over an 8-hour period of sleep at 30-second intervals

Time frame: 8 hours

ArmMeasureValue (NUMBER)
Zansors® Sleep Screening DevicePositive Predictive Value (PPV)0.692 positive predictive value
Secondary

Sensitivity

Sensitivity of Zansors' device to detect apnea events compared to gold-standard polysomnography over an 8-hour period of sleep at 30-second intervals

Time frame: 8 hours

ArmMeasureValue (NUMBER)
Zansors® Sleep Screening DeviceSensitivity75 percentage of true positives

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026